InVivo Therapeutics Holdings Corp (NVIVQ)

[MDizzle]

InVivo Therapeutics Opens First Ex-U.S. Site in Canada for INSPIRE Study

8:00 AM ET 7/14/16 | BusinessWire

InVivo Therapeutics Holdings Corp. (NVIV) today announced that it has received approval from the Toronto Western Hospital's Research Ethics Board to enroll patients as part of the INSPIRE study. Michael Fehlings, M.D., Ph.D., has been named Principal Investigator at the site. Dr. Fehlings is currently Director of the Spinal Program at Toronto Western Hospital at the University Health Network, Professor in the Department of Surgery, full member of the Institute of Medical Sciences School of Graduate Studies, a Scholar in the McLaughlin Centre of Molecular Medicine, a Scientist in the McEwen Centre for Regenerative Medicine, a Senior Scientist at the Krembil Research Institute, Director of the University of Toronto Neuroscience Program, Co-Director of the University of Toronto Spine Program, and Krembil Chair in Neural Repair and Regeneration. Dr. Fehlings has published over 400 peer-reviewed articles principally in the area of spinal cord injury and complex spinal surgery.

Dr. Fehlings said, "Spinal cord injury is a devastating condition for which innovative bioengineered regenerative strategies hold considerable promise. Accordingly, our centre is pleased to assist with translating this exciting technology for people with paralysis from spine trauma into the clinic."

"We are pleased to welcome Dr. Fehlings, one of the global leaders in spinal cord injury research, and the Toronto Western Hospital to the INSPIRE study," Mark Perrin, InVivo's CEO and Chairman, said.